<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451905</url>
  </required_header>
  <id_info>
    <org_study_id>GLP1-PSO</org_study_id>
    <nct_id>NCT01451905</nct_id>
  </id_info>
  <brief_title>GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <brief_summary>
    <textblock>
      To examine GLP-1 receptors in skin of psoriasis patients compared with the skin of humans&#xD;
      with no skin disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in PASI and DLQI</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI</condition>
  <arm_group>
    <arm_group_label>Psoriasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.</description>
    <arm_group_label>Psoriasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        4.3 Inclusion Criteria&#xD;
&#xD;
          -  Caucasians above 18 years of age&#xD;
&#xD;
          -  Plaque psoriasis&#xD;
&#xD;
          -  PASI score &gt;10&#xD;
&#xD;
          -  No treatment or stable treatment of psoriasis during at least 3 months before&#xD;
             inclusion&#xD;
&#xD;
          -  Steady weight through 3 months with a body mass index (BMI) above 27 kg/m2&#xD;
&#xD;
          -  Normal blood pressure&#xD;
&#xD;
          -  Spiral or hormonal birth control for fertile women during the entire treatment period&#xD;
             and at least 3 days after the end of the treatment period (~5 times the plasma&#xD;
             half-life) 4.4 Exclusion Criteria&#xD;
&#xD;
          -  Psoriasis arthritis&#xD;
&#xD;
          -  Fasting plasma glucose &gt; 7.5 mmol/L or HbA1c &gt; 7.5%&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Treatment for type 2 diabetes with GLP-1-based medicine (DDP-4-inhibitors or&#xD;
             GLP-1-receptor-agonists)&#xD;
&#xD;
          -  Heart failure, NYHA class III-IV&#xD;
&#xD;
          -  Uraemia, end-stage renal disease, or any other cause of impaired renal function with&#xD;
             s-creatinine &gt;150 µM and/or albuminuria&#xD;
&#xD;
          -  Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase&#xD;
             (ASAT) &gt;2 x upper normal serum levels)&#xD;
&#xD;
          -  Anaemia&#xD;
&#xD;
          -  Acute or chronic pancreatitis&#xD;
&#xD;
          -  Struma or thyroid cancer&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Inability to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Annesofie Faurschou, MD PhD</last_name>
    <phone>+45 39773977</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lone Skov, Prof</last_name>
      <phone>+45 39773977</phone>
      <email>losk@geh.regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Annesofie Faurschou</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

